SCYNEXIS is a biotechnology company. Co. is developing its main product candidate, ibrexafungerp, as an intravenous/oral agent for multiple fungal indications in both the community and hospital settings. The U.S. Food and Drug Administration has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and Co. has commenced the commercialization of BREXAFEMME in the U.S. Co. also is continuing late-stage clinical development of ibrexafungerp for multiple indications, including the treatment of invasive fungal infections caused by Candida spp. (including C. auris) and Aspergillus spp. in hospitalized patients.